\
&
Contact us
\
&
Contact us
Published on | 1 year ago
ProgrammesThe European Union and the Republic of Korea announce support for four jointly funded projects in semiconductors as a deliverable of the EU-Republic of Korea Digital Partnership.
The projects will advance heterogeneous integration technologies i.e. technologies combining multiple components onto one chip as well as neuromorphic computing technologies i.e. technologies imitating the functioning of the human brain.
The projects will bring together research and innovation partners from the EU and the Republic of Korea to set up joint research teams, provide shared access to cutting-edge facilities and infrastructures and organise knowledge exchange through events.
The selected joint EU-ROK projects are:
These are 3-year projects co-funded by the Chips Joint Undertaking under Horizon Europe, and the National Research Foundation of Korea (NRF).
For more information on the projects please consult the European Commission's news article.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.
